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We investigated the clinical efﬁcacy of vertebroplasty (VP) for the treatment of osteoporotic vertebral
compression fracture (OVCF). We searched the online databases such as MEDLINE, EMBASE, EBSCO,
Springer, Ovid and Cochrane library citations up to May 2012 and 5 eligible studies were included in this
study. The meta-analysis was conducted using software RevMan 5.0. For the continuous data, the
weighted mean difference (WMD) and its 95% conﬁdence interval (CI) were calculated and the odds ratio
(OR) and the corresponding 95% CI were calculated for the dichotomous data. The results demonstrated
that the Visual Analogue Scale (VAS) score of patients treated with VP was signiﬁcantly lower than that
treated with traditional treatment at each time point (one week: WMD ¼ 2.55, 95% CI, 3.08 to 2.02,
P < 0.0001; 12 weeks: WMD ¼ 0.90, 95% CI, 1.22 to 0.57, P < 0.0001; 24 weeks: WMD ¼ 1.75, 95%
CI, 2.30 to 1.19, P < 0.0001; 48 weeks: WMD ¼ 1.75, 95% CI, 2.30 to 1.19, P < 0.001). For The
incidence of adjacent vertebral fracture, the overall estimate (OR ¼ 2.06, 95% CI: 0.26 to 16.29, P ¼ 0.50)
indicated that there was no statistically signiﬁcant difference between VP and traditional treatment. In
conclusion, the OVCF patients treated by VP had statistically signiﬁcant improvements in pain relief
compared with the traditional treatment and there was the similar incidence of adjacent vertebral
fracture between the patients treated by VP and traditional treatment.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Osteoporosis (porous bones) as a systemic skeletal disease, is
characterized by low bone mass and microarchitectural deteriora-
tion of bone tissue with a consequent increase of bone fragility and
susceptibility to fractures [1]. Vertebral compression fracture (VCF)
is the most common complication of osteoporosis [2]. The risk of
VCF was increased with age [3]. Osteoporotic VCF (OVCF) is a
leading cause of disability and morbidity in the elderly [4]. As the
most common fractures in the elders with osteoporosis, it wasics, Tangdu Hospital of the
Xi'an 710038, Shannxi Prov-
.
by Elsevier Ltd. All rights reservedoccurred in 20% of people older than 70 years and in 16% of post-
menopausal women [5]. It was reported that there were more than
700,000 osteoporotic VCFs per year in the United States and
approximately 85% of these fractures were due to primary osteo-
porosis [6].
Traditional treatments for the patients with OVCF include bed
rest, oral or parenteral analgesics, muscle relaxants, external back
bracing, and physical therapy [7]. Because the narcotic agents and a
variety of expensive spinal orthoses are commonly used in the
traditional treatment [8], the effectiveness of them may be limited
due to the high cost and the long-time treatment. Thus, ﬁnding a
treatment with high efﬁcacy and low cost is a major task in clinical
study for OVCF.
Vertebroplasty (VP) is a minimally invasive technique in verte-
bral body lesion therapy. It was reported that VP could effectively.
Fig. 1. The ﬂow diagram of literature screening.
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the efﬁcacy and safety of VP is afﬁrmed constantly [13e15], the
disputes on the efﬁcacy and complications of VP are still existed in
recent studies. The study of Ploeg et al. reported that there were
insufﬁcient evidence to reliably assess efﬁcacy of VP [16], while
Blasco J et al. reported that VP achieved faster pain relief but was
associated with a higher incidence in vertebral fractures. Therefore,
we conducted a meta-analysis to statistically analyze the data from
the recent studies in order to provide more reliable basis for the
clinical efﬁcacy of VP in treating OVCF.
2. Materials and methods
2.1. Search criteria and strategies
We retrieved the databases such as MEDLINE, EMBASE, EBSCO,
Springer, Ovid and Cochrane library up to May 2012. The keywords
included “vertebroplasty”, “osteoporosis” and “vertebral compres-
sion fracture”. The studies should meet the following inclusion
criteria: (1) researches were clinical randomized controlled trials
(RCTs) related to VP in the treatment of OVCF; (2) studies were
published abroad; (3) the patients in experimental group should be
treated with VP and the patients in the control group were treated
by the traditional treatment including bed rest, oral anti-
osteoporotic drugs and painkillers, wearing the spinal orthosis,
reset, or functional exercise; (4) the Visual Analogue Scale (VAS)
score for pain or/and complications were investigated. The studies
were excluded if (1) the patients in the studies suffered cardio-
pulmonary dysfunction and other serious diseases, (2) therewas no
speciﬁc data except the curves of the indicators, (3) the patients
were not conﬁrmed by diagnosis and (4) the studies were non-
RCTs.
2.2. Quality assessment and data extraction
Two investigators independently assessed the study quality and
extracted the data. Disagreements were resolved by discussion. The
study quality was evaluated based on the random allocation
method, blind method and evaluation of withdrawal. The extracted
data included general information (ﬁrst author, year and region)
and study characteristics (design, follow-up time, sample size, age
and gender of subjects and the data of outcomes).
2.3. Statistical analysis
The meta-analysis was conducted using the Cochrane software
RevMan 5.0. For continuous data, the weighted mean difference
(WMD) and its 95% conﬁdence interval (CI) were calculated. For
dichotomous data, the odds ratio (OR) and the corresponding 95%
CI were calculated. The Z-test was used for assessing the signiﬁ-
cance of the pooled OR and WMD, with P < 0.05 considered sta-
tistically signiﬁcant. Heterogeneity among the included studies was
evaluated by chi-square test and I2 statistic. If no signiﬁcantly
heterogeneity (P > 0.05 or I2 < 50%) was found, the effect size was
pooled based on the ﬁxed-effects model. Otherwise, random-
effects model was used.
3. Results
3.1. Literature search
After the initial search in the databases, a total of 1073 poten-
tially relevant literature were identiﬁed. Then 12 articles were
remained by omitting the duplicated and obviously irrelevant
literature. Based on exclusion and inclusion criteria, two reviewers,one non-RCT and four literature which did not report the treatment
of OVCF with VP were excluded. As a result, 5 literature were
identiﬁed (Fig. 1).3.2. Characteristics of included studies
According to the inclusion and exclusion criteria, a total of ﬁve
eligible studies [17e21] were included in this meta-analysis. The
published year was ranged from 2007 to 2012. All the included
subjects were elders aged over 50 years old. The duration of follow-
up in these studies was ranged from 2 weeks to 36 months. All the
included studies were RCTs. Among them, the study of Farrokhi
et al. [18] was a single-blind RCT and the study of Rousing et al. [20]
was a double-blind RCT. The other three studies did not deﬁne the
blind method (Table 1).3.3. Statistical analysis
3.3.1. Comparison of VAS score
Two included studies [18,19] investigated the VAS score at one
week after treatment. Fixed effects model was used because no
signiﬁcant heterogeneity was found (P¼ 0.06, I2¼ 71%). The pooled
estimate (WMD ¼ 2.55, 95% CI: 3.08 to 2.02, P < 0.00001)
showed that there was statistically signiﬁcant difference between
the experimental and control group. The result indicated that the
VAS score of the patients in VP group were signiﬁcantly lower than
that in control group at one week after treatment (Fig. 2A).
The VAS score at 12 weeks after treatment was shown in two
included studies [19,20]. There was no signiﬁcant heterogeneity
among the studies (P ¼ 0.18, I2 ¼ 44%), so ﬁxed effects model was
used. The pooledWMD (0.90, 95% CI:1.22 to0.57, P< 0.00001)
showed that the statistically signiﬁcant difference was existed be-
tween the two groups. It suggested that the VAS score of patients in
VP group was signiﬁcantly lower than that in control group at 12
weeks after treatment (Fig. 2B).
Two included studies [18,19] involved in VAS score at 24 weeks
after treatment. Fixed effects model was used for no signiﬁcant
heterogeneity between the studies (P ¼ 0.59, I2 ¼ 0%). The overall
WMD was 1.75 (95% CI: 2.30 to 1.19, P < 0.00001), which
showed the statistically signiﬁcant difference between the two
groups. It indicated that the VAS score of the patients in VP group
was signiﬁcantly lower compared with that in control group at 24
weeks after treatment (Fig. 2C).
A total of three studies [18e20] showed the VAS score at 48
weeks after treatment. Fixed effects model was used for no sig-
niﬁcant heterogeneity among the studies (P ¼ 0.06, I2 ¼ 65%). The
pooled estimate (WMD ¼ 1.12, 95% CI: 1.43 to 0.81,
P < 0.00001) showed a statistically signiﬁcant difference between
Table 1
The characteristics of the included studies.
First
author
year Region Sample size
Experiment/control
Age
Experiment/control
Female (%)
Experiment/control
Design Duration
of follow-up
Indicators
Blasco 2012 Europe 64/61 71.33 ± 9.95/
75.27 ± 8.53
73/82 RCT 12 months Adjacent vertebral
fracture incidence
Farrokhi 2011 Asia 40/42 72 (59e90)/
74 (55e87)
30/30 Single-blind RCT 36 months VAS score at 1, 24
and 48 weeks after
treatment, adjacent
vertebral fracture
incidence
Klazen 2010 Europe 97/93a
92/86b
89/81c
86/77d
75.2 ± 9$8/
75.4 ± 8$4
69/69 RCT 12 months VAS score at 1, 12,
24 and 48 weeks
after treatment
Rousing 2009 Europe 23/23e
22/22f
23/22g
80 (65e96)/
80 (71e93)
NA Double-blind RCT 3 months VAS score at 12 and
48 weeks after
treatment, adjacent
vertebral fracture
incidence
Voormolen 2007 Europe 18/16 72 (59e84)/
74 (55e88)
14/14 RCT Two weeks Adjacent vertebral
fracture incidence
NA: not provided; VAS: visual analogue scale; RCT: randomized controlled trial.
a Sample size of Klazen et al. in the indicator of VAS score at 1 week after treatment.
b Sample size of Klazen et al. in the indicator of VAS score at 12 week after treatment.
c Sample size of Klazen et al. in the indicator of VAS score at 24 week after treatment.
d Sample size of Klazen et al. in the indicator of VAS score at 48 week after treatment.
e Sample size of Rousing et al. in the indicator of VAS score at 12 week after treatment.
f Sample size of Rousing et al. in the indicator of VAS score at 48 week after treatment.
g Sample size of Rousing et al. in the indicator of adjacent vertebral fracture incidence.
Fig. 2. Forest plots of VAS score after treatment. A: VAS score at one week after treatment; B: VAS score at 12 weeks after treatment; C: VAS score at 24 weeks after treatment; D:
VAS score at 24 weeks after treatment.
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Fig. 3. Forest plots of the adjacent vertebral fracture incidence.
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of the patients in VP group was signiﬁcantly lower than that in
control group at 48 weeks after treatment (Fig. 2D).
3.3.2. Comparison of complications
Four included studies [17,18,20,21] reported the incidence of
adjacent vertebral fracture after treatment. Signiﬁcant heteroge-
neity (P ¼ 0.03; I2 ¼ 67%) was found among the studies, so random
effects model was used. The overall estimate (OR ¼ 2.06, 95% CI:
0.26 to 16.29, P ¼ 0.50) indicated that there was no statistically
signiﬁcant difference between the two groups for the adjacent
vertebral fracture incidence (Fig. 3).
In addition, Farrokhi MR et al. observed that epidural cement
leakage caused severe right lower-extremity pain and weakness in
one patient [18]. Meanwhile, no other serious complications or
adverse events were reported in all the included studies.
4. Discussion
Lowback pain is themain symptom of OVCF, and long-term pain
will seriously inﬂuence the life quality of the OVCF patients [22].
The causes of pain in OVCF patients are complicated, which may
related to nerve endings irritated by slight movement of vertebral
fracture [23e25]. In this study, the results showed that the VAS
score of patients in VP group was signiﬁcantly lower than that in
traditional treatment group at each time point. It suggested the
OVCF patients treated by VP had statistically signiﬁcant improve-
ments in pain relief. It was consistent with the result of other
published studies [11,26,27]. The mechanism of VP in treating OVCF
patients may be associated with the characteristics of VP and the
causes of pain in OVCF patients. We speculated that, ﬁrstly, the
curing material (usually polymethyl methacrylate) can ﬁx the mi-
cro fractures, strengthen the vertebral body and relieve nerve
irritation, then large amounts of heat is released with the concre-
tion and agglomeration of polymethyl methacrylate and the tem-
perature is increased [28,29]. The increase of temperature
ascension, extrusion of the solid and chemical toxicity of the pol-
ymethyl methacrylate may lead to the necrosis of nerve endings, so
as to relieve pain [30,31].
In addition, the present study showed no difference was found
in the incidence of adjacent vertebral fracture between VP and
traditional treatment group. Meanwhile, severe right lower-
extremity pain and weakness caused by the leakage of cement
was observed by Farrokhi MR et al. [18]. It has been reported that
leakage of cement outside the vertebral body was markedly com-
mon in VP [16]. Although no other serious complications or adverse
events were reported in all the included studies in this meta-
analysis, some potentially rare complications such as pulmonary
embolism caused by the leakage of cement can be devastating [32].
Therefore, more studies must be done to investigate the low inci-
dence but high devastating complications.
Some limitations of this meta-analysis should be mentioned.
First, for each indicator, the number of the included studies andsample size was small. The result of this study may be questioned
and more studies with large sample size were required to verify
these result. Second, the publication bias was not assessed because
of small number of included studies for each indicator. Third,
random method of some trials was undeﬁned. The results of this
studymay be affected by the different study designs of the included
studies. Moreover, the sources of heterogeneity need to be explored
in the further studies.
5. Conclusion
Based on the result in this study, we concluded that the OVCF
patients treated by VP had statistically signiﬁcant improvements in
pain relief and similar incidence of adjacent vertebral fracture
compared with the traditional treatment.
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